BRIEF-Repros Therapeutics jumps in premarket after testosterone drug hits main goals of study

NEW YORK, March 28 Thu Mar 28, 2013 8:10am EDT

NEW YORK, March 28 (Reuters) - Repros Therapeutics Inc : * Jumps 75.3 to $16 in premarket after testosterone drug hits main goals of study

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.